Cantor Fitzgerald Reaffirms “Overweight” Rating for MiMedx Group (NASDAQ:MDXG)

MiMedx Group (NASDAQ:MDXG)‘s stock had its “overweight” rating restated by analysts at Cantor Fitzgerald in a note issued to investors on Monday,Benzinga reports. They currently have a $8.00 price objective on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 87.35% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Wall Street Zen downgraded MiMedx Group from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. Citizens Jmp reduced their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of MiMedx Group in a report on Thursday. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

MiMedx Group Stock Performance

Shares of MDXG stock opened at $4.27 on Monday. The stock has a market cap of $622.40 million, a P/E ratio of 106.78 and a beta of 1.45. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The company has a fifty day moving average price of $4.04 and a two-hundred day moving average price of $4.14. MiMedx Group has a one year low of $3.03 and a one year high of $7.97.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). The company had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. As a group, equities analysts predict that MiMedx Group will post -0.1 EPS for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of institutional investors have recently made changes to their positions in the company. Kemnay Advisory Services Inc. bought a new position in shares of MiMedx Group during the fourth quarter worth approximately $48,000. Sunbelt Securities Inc. acquired a new stake in shares of MiMedx Group during the first quarter worth $42,000. Jain Global LLC bought a new stake in shares of MiMedx Group in the fourth quarter valued at about $73,000. E Fund Management Co. Ltd. acquired a new position in shares of MiMedx Group in the second quarter valued at about $45,000. Finally, Virtu Financial LLC bought a new position in MiMedx Group during the fourth quarter worth about $78,000. Institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.